Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Impact of Progression-Free Survival at 24 Months on Subsequent Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Supplementary Analysis of JCOG0601

Ayumi Fujimoto, Wataru Munakata, Gakuto Ogawa, Tomotaka Suzuki, Kazuyuki Shimada, Tsutomu Kobayashi, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Dai Maruyama, Hirokazu Nagai

Blood (2023) 142 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2023-173433

Published: 2023

Journal Articles

The Prognostic Impact of Relative Dose Intensity of Vincristine in R-CHOP for Untreated Patients with Diffuse Large B-Cell Lymphoma: A Supplementary Analysis of JCOG0601

Takahiro Nakashima, Tomotaka Suzuki, Gakuto Ogawa, Kazuyuki Shimada, Tsutomu Kobayashi, Dai Maruyama, Wataru Munakata, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Hirokazu Nagai

Blood (2023) 142 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2023-174354

Published: 2023

Journal Articles

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

Blood (2023) 142 (Supplement 1): 1724.

https://doi.org/10.1182/blood-2023-178551

Published: 2023

Journal Articles

Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)

Blood (2022) 140 (Supplement 1): 3718–3720.

https://doi.org/10.1182/blood-2022-157006

Published: 2022

Journal Articles

Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

Blood (2018) 132 (Supplement 1): 4194.

https://doi.org/10.1182/blood-2018-99-110201

Published: 2018

Journal Articles

A Phase II Study of THP-COP (pirarubicin, cyclophosphamide, vincristine and prednisolone) in Patients with Newly Diagnosed Advanced Peripheral T-Cell Lymphoma: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group (HMCSG)

Michinori Ogura, MD PhD, Ken Ohmachi, MD, Ritsuro Suzuki, MD PhD, Yoshiko Atsuta, MD PhD, Tatsuya Ito, MD, Kazuma Ohyashiki, MD, Shingo Yano, MD PhD, Michihiro Hidaka, MD PhD, Kiyoshi Ando, MD PhD, Noriko Fukuhara, MD PhD, Yoshihisa Morishita, MD PhD, Takayo Suzuki, MD PhD, Kunihiro Tsukasaki, MD PhD, Naoki Kobayashi, MD PhD, Kenji Tsukamoto, MD, Yukiyasu Ozawa, MD PhD, Tomomitsu Hotta, MD PhD, Tomohiro Kinoshita, MD PhD

Blood (2017) 130 (Supplement 1): 2789.

https://doi.org/10.1182/blood.V130.Suppl_1.2789.2789

Published: 2017

Journal Articles

Limited-Stage Mantle Cell Lymphoma

Ritsuro Suzuki, MD PhD, Dai Chihara, MD PhD, Naoko Asano, MD PhD, Ken Ohmachi, MD, Tomohiro Kinoshita, MD PhD, Kosei Matsue, MD PhD, Junji Suzumiya, MD PhD, Michinori Ogura

Blood (2016) 128 (22): 5330.

https://doi.org/10.1182/blood.V128.22.5330.5330

Published: 2016

Journal Articles

Phase I Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Dai Maruyama, MD PhD, Kensei Tobinai, MD PhD, Kiyoshi Ando, MD PhD, Ken Ohmachi, MD, Michinori Ogura, MD PhD, Toshiki Uchida, MD PhD, Tadashi Nakanishi, Masayuki Namiki, PhD

Blood (2015) 126 (23): 2724.

https://doi.org/10.1182/blood.V126.23.2724.2724

Published: 2015

Journal Articles

Simplified MIPI Is a Valid Prognostic Index In The Rituximab Era: Multicenter MCL Study In Japan

Dai Chihara, MD, PhD, Naoko Asano, MD, Ph.D., Tomohiro Kinoshita, MD, PhD, Yoshinobu Maeda, MD, PhD, Kosei Matsue, MD, PhD, Ken Ohmachi, M.D., Masataka Okamoto, MD, PhD, Ishikazu Mizuno, MD, Toshiki Uchida, MD, PhD, Hirokazu Nagai, MD, PhD, Michinori Ogura, M.D., Ph.D., Ritsuro Suzuki, MD

Blood (2013) 122 (21): 4257.

https://doi.org/10.1182/blood.V122.21.4257.4257

Published: 2013

Journal Articles

Novel Prognostic Model Of Primary Mediastinal Large B-Cell Lymphoma (PMBL): A Multicenter Cooperative Retrospective Study In Japan

Tomohiro Aoki, M.D., Koji Izutsu, MD, PhD, Ritsuro Suzuki, MD, Chiaki Nakaseko, M.D., Ph.D., Hiroshi Arima, M.D., Kazuyuki Shimada, M.D., Ph.D., Makoto Sasaki, M.D., Ph.D., Jun Takizawa, M.D., Ph.D., Kinuko Mitani, M.D., Ph.D., Tadahiko Igarashi, M.D., Yoshinobu Maeda, M.D., Ph.D., Fumihiro Ishida, M.D., Nozomi Niitsu, M.D., Ph.D., Ken Ohmachi, M.D., Hirotaka Takasaki, M.D., Naoya Nakamura, M.D., Ph.D., Tomohiro Kinoshita, MD, PhD, Shigeo Nakamura, MD, PhD, Michinori Ogura, M.D., Ph.D.

Blood (2013) 122 (21): 638.

https://doi.org/10.1182/blood.V122.21.638.638

Published: 2013

Journal Articles

Discovery of Unique Biomarkers That Predict Bortezomib-Induced Peripheral Neuropathy: The Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan

Takashi Watanabe, MD, PhD, Masato Mitsuhashi, MD, PhD, Morihiko Sagawa, MD, PhD, Kenshi Suzuki, MD, PhD, Masaki Ri, MD, PhD, Masahiro Abe, MD, PhD, Ken Ohmachi, MD, Yasunori Nakagawa, MD, PhD, Shingen Nakamura, MD, Mizuki Chosa, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2012) 120 (21): 1816.

https://doi.org/10.1182/blood.V120.21.1816.1816

Published: 2012

Journal Articles

A Biomarker Obtained From Whole Peripheral Blood Predicts Response to Bortezomib: Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan.

Blood (2012) 120 (21): 2954.

https://doi.org/10.1182/blood.V120.21.2954.2954

Published: 2012

Journal Articles

Durable Responses with Bendamustine Monotherapy In Patients with Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mantle-Cell Lymphoma (MCL): Updated Follow-up Data From a Japanese Multicenter Phase II Study

Kuniaki Itoh, MD, PhD, Kiyoshi Ando, MD, PhD, Michinori Ogura, MD, PhD, Kenichi Ishizawa, MD, PhD, Takashi Watanabe, MD, PhD, Naokuni Uike, MD, PhD, Yasuhito Terui, MD, PhD, Kensuke Usuki, MD, PhD, Hirokazu Nagai, MD, PhD, Nobuhiko Uoshima, MD, PhD, Nobuko Kubota, MD, PhD, Ken Ohmachi, MD, PhD, Toshiki Uchida, MD, PhD, Joji Yamamoto, MD, PhD, Ilseung Choi, MD, PhD, Kensei Tobinai, MD, PhD

Blood (2010) 116 (21): 4884.

https://doi.org/10.1182/blood.V116.21.4884.4884

Published: 2010

Journal Articles

Bendamustine Is Highly Effective for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mantle Cell Lymphoma (MCL): Final Results of a Japanese Multicenter Phase II Study.

Michinori Ogura, MD, PhD, Toshiki Uchida, MD, PhD, Kiyoshi Ando, MD, PhD, Ken Ohmachi, MD, PhD, Kuniaki Itoh, MD, PhD, Nobuko Kubota, MD, PhD, Kenichi Ishizawa, MD, PhD, Joji Yamamoto, MD, PhD, Takashi Watanabe, MD, PhD, Naokuni Uike, MD, PhD, IIseung Choi, MD, PhD, Yasuhito Terui, MD, PhD, Kensuke Usuki, MD, PhD, Hirokazu Nagai, MD, PhD, Nobuhiko Uoshima, Kensei Tobinai, MD, PhD

Blood (2009) 114 (22): 3694.

https://doi.org/10.1182/blood.V114.22.3694.3694

Published: 2009

NARROW

Impact of Progression-Free Survival at 24 Months on Subsequent Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Supplementary Analysis of JCOG0601

The Prognostic Impact of Relative Dose Intensity of Vincristine in R-CHOP for Untreated Patients with Diffuse Large B-Cell Lymphoma: A Supplementary Analysis of JCOG0601

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)

Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

A Phase II Study of THP-COP (pirarubicin, cyclophosphamide, vincristine and prednisolone) in Patients with Newly Diagnosed Advanced Peripheral T-Cell Lymphoma: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group (HMCSG)

Limited-Stage Mantle Cell Lymphoma

Phase I Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Simplified MIPI Is a Valid Prognostic Index In The Rituximab Era: Multicenter MCL Study In Japan

Novel Prognostic Model Of Primary Mediastinal Large B-Cell Lymphoma (PMBL): A Multicenter Cooperative Retrospective Study In Japan

Discovery of Unique Biomarkers That Predict Bortezomib-Induced Peripheral Neuropathy: The Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan

A Biomarker Obtained From Whole Peripheral Blood Predicts Response to Bortezomib: Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan.

Durable Responses with Bendamustine Monotherapy In Patients with Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mantle-Cell Lymphoma (MCL): Updated Follow-up Data From a Japanese Multicenter Phase II Study

Bendamustine Is Highly Effective for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mantle Cell Lymphoma (MCL): Final Results of a Japanese Multicenter Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only